NCT05016947 - Venetoclax Plus Inotuzumab for B-ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

December 23, 2025

Study Completion Date

June 23, 2026

Conditions

B-cell Acute Lymphoblastic LeukemiaB-Cell LymphomaALL

Interventions

DRUG

Venetoclax

Tablet, taken by mouth

DRUG

Dexamethasone

Taken orally

DRUG

Inotuzumab Ozogamicin

Intravenous infusion

Trial Locations (2)

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston